ResMed Stock News
$229.50
1.58%
today
NYSE,
Dec 30, 10:10 pm CET
ResMed Stock News
Negative
Investopedia
●
7 days ago
Shares of ResMed (RMD) and Inspire Medical Systems (INSP) fell Monday as the companies behind products to treat sleep apnea faced a new threat from weight-loss drugs.
Positive
Schaeffers Research
●
7 days ago
Eli Lilly and Co (NYSE:LLY) is in focus today, after the U.S. Food & Drug Administration (FDA) approved its weight-loss drug, Zepbound, to treat obstructive sleep apnea in adults with obesity -- the first such treatment in the country.
Neutral
GlobeNewsWire
●
27 days ago
Dublin, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The "Canada Sleep Apnea Devices Market, By Region, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ResearchAndMarkets.com's offering. Canada Sleep Apnea Devices Market was valued at USD 338.54 Million in 2023 and is expected to reach USD 465.53 Million by 2029 with a CAGR of 5.41%
Positive
Seeking Alpha
●
28 days ago
The SPDR S&P 500 ETF Trust posted a strong gain of 5.96% in November, resuming its strong run in 2024. The Top 15 dividend growth stocks for December 2024 offer an average dividend yield of 1.2% and appear to be about 22% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 12.41% compound annual growth rate.
Neutral
GlobeNewsWire
●
about 2 months ago
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 3:30 p.m. (Pacific Standard Time) at the Terranea Resort Hotel in Rancho Pal...
Positive
Seeking Alpha
●
about 2 months ago
The SPDR S&P 500 ETF Trust posted a loss of 0.89% in October, putting a pause on its strong run in 2024. The Top 15 dividend growth stocks for November 2024 offer an average dividend yield of 1.24% and appear to be about 23% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved an 11.33% compound annual growth rate.
Positive
Investors Business Daily
●
2 months ago
S&P 500 giant JPMorgan Chase has been hovering near a buy point since a Q3 earnings beat. Several stocks are in or near buy zones.
Positive
The Motley Fool
●
2 months ago
Here are three attractive stocks to buy that will give you a healthy mix of growth and dividends.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
